10 January 2020
: Case report
Diagnostic Challenges and Treatment Options for Cutaneous T Cell Pseudolymphoma: A Case Study with Rituximab Treatment
Mistake in diagnosis, Diagnostic / therapeutic accidents, Rare disease
Dārta Balode12ABEF*, Ludmila Beļajeva2B, Vanessa Ruesseler3BE, Alexander Quaas3B, Sandra Lejniece12ABDEDOI: 10.12659/AJCR.919616
Am J Case Rep 2020; 21:e919616
Abstract
BACKGROUND: Pseudolymphoma is a rare disorder that can mimic lymphoma both clinically and histologically. It usually affects middle-aged females. Since pseudolymphoma is a rare disorder not only is diagnosing the condition difficult, but there is also a lack of standardized treatment guidelines. In the literature, anti-CD20 monoclonal antibody rituximab is described as an effective treatment option.
CASE REPORT: 46-year-old female fell ill suddenly with swelling and enlargement of her chin. Multiple skin biopsies were done, which were re-evaluated multiple times as well. Each ended with a new diagnosis for the patient. Finally, in the last revision of biopsy material, pseudolymphoma was confirmed. The patient received multiple courses of corticosteroid treatments – locally and systemically – without long lasting effect. After diagnosis of pseudolymphoma, the patient was started on intravenous rituximab and this treatment was effective.
CONCLUSIONS: Cutaneous pseudolymphoma is a diagnostic challenge. Rituximab is a treatment option for refractory pseudolymphoma. Since there are no treatment guidelines for pseudolymphoma, more clinical studies are needed to establish best treatment options for these patients. Therefore, each reported clinical case is important.
Keywords: Genes, T-Cell Receptor, Pathology, Pseudolymphoma, Antibodies, Monoclonal, Biopsy, Chin, Diagnosis, Differential, Diagnostic Errors, Lymphoma, T-Cell, Cutaneous, Rare Diseases, rituximab, Skin Diseases
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947628
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947148
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946611
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.948042
Most Viewed Current Articles
21 Jun 2024 : Case report
97,828
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
52,727
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
32,839
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
18 Feb 2024 : Case report
23,613
DOI :10.12659/AJCR.943030
Am J Case Rep 2024; 25:e943030